drugset / Trial / NCT05247216
A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and investigate the efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of Hemay007 in Patients with moderate to severe Rheumatoid Arthritis who are on a stable dose of DMARDs.
Timeline
- Start
- 2021-03-26
- Primary completion
- 2023-06-22
- Completion
- 2023-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hemay007 | Unknown | 600 mg | Oral |
| Subject | Hemay007 | Unknown | 800 mg | Oral |
| Subject | Hemay007 | Unknown | 1200 mg | Oral |